Congenital defects, tumors, surgeries, and inflammatory diseases are possible causes of such blockages
Conclusion: Disclosure of interest: All authors: nothing to disclose E-Posters - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.01 - ACUTE MANAGEMENT - Neither thrombolysis nor thrombectomy P2131 - ESOC25-2296 MANAGEMENT OF TIA AND STROKE ATTACK RISK STRATIFICATION: EXPERIENCE IN AN ALGERIAN PERIPHERAL HOSPITAL Amina Behiri 1 , Sonia Nouioua 1 , Feroudja Ramdane Cherif 1 1 Department of Neurology El Maham, cherchell, Algeria Background and Aims: The aim of our study is to evaluate the management efficiency for TIA in an Algerian peripheral hospital, and to analyze the risk factors associated with outcome to an ischemic stroke
Molecular Formula: CHCuNO (peptide-copper complex)
Products containing BPC-157 might be labeled as research chemicals and carry statements such as Not for human consumption, Research use only, or For research purposes only. Service Members should avoid using research chemicals or any products containing prohibited ingredients, regardless of how they are taken (by mouth, injection, or nasal spray)
Body Protection Compound 157 (BPC-157) is a synthetic peptide chain consisting of 15 amino acids
Rotating injection sites each time helps minimize this issue
